When we further classified patients based on their combined tumor CDKN2A locus methylation/expression status, comparing patients with either hypermethylated CDKN2A or high RNA levels of ARF/INK4a to those with CDKN2A hypomethylation and low ARF+INK4a expression, we found a stronger association with risk of LRR (Log‐rank test P = 0.01; Fig. 5D). The gene discussed is CDKN2A; the disease is neoplasm.